Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease

Leuk Res. 2017 Nov;62:12-16. doi: 10.1016/j.leukres.2017.09.020. Epub 2017 Sep 27.


Plasmablastic lymphoma (PBL) is a rare and hard to treat disease. With current standard chemotherapeutic regimens, PBL is associated with a median overall survival of 12-15 months. We performed a systematic review of the literature through March 31, 2017 looking for patients with a diagnosis of PBL who were treated with bortezomib, alone or in combination. We identified 21 patients, of which 11 received bortezomib in the frontline setting and 10 received bortezomib in the relapsed setting. Eleven patients were HIV-positive and 10 were HIV-negative. The overall response rate to bortezomib-containing regimens was 100% in the frontline setting and 90% in the relapsed setting. Furthermore, the 2-year overall survival of patients treated upfront was 55%, and the median OS in relapsed patients was 14 months. Although the sample size is small, we believe our results are encouraging and should serve as rationale to investigate bortezomib-based regimens in patients with PBL.

Keywords: Bortezomib; Plasmablastic lymphoma; Survival; Systematic review.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Bortezomib / therapeutic use*
  • Humans
  • Plasmablastic Lymphoma / drug therapy*
  • Plasmablastic Lymphoma / mortality
  • Treatment Outcome


  • Antineoplastic Agents
  • Bortezomib